Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
SALT LAKE CITY, May 31, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four Seasons Hotel in Chicago, Illinois.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
